Prevention of Radiocontrast Nephropathy with N-Acetylcysteine in Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized, Controlled Trials

American Journal of Kidney Diseases

Volumn 43, Issue 1, 2004, Pages 1-9

  Alonso, Alvaro ^b   Lau, Joseph ^b   Jaber, Bertrand L ^b   Weintraub, Andrew ^b   Sarnak, Mark J ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Acute renal failure (ARF); Chronic kidney disease (CKD); Contrast media; Meta analysis; N acetylcysteine (NAC); Radiocontrast nephropathy (RCN)

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; CREATININE;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DATA BASE; DOUBLE BLIND PROCEDURE; HUMAN; IATROGENIC DISEASE; KIDNEY DISEASE; MEDLINE; META ANALYSIS; PUBLICATION; RADIOCONTRAST NEPHROPATHY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS;

EID: 0347990333     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.09.009     Document Type: Article

References (56)

1. Nash K, Hafeez A, Hou S: Hospital-acquired renal insufficiency. Am J Kidney Dis 39:930-936, 2002
2. Diaz-Sandoval LJU, Kosowsky BD, Losordo DW: Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 89:356-358, 2002
3. McCullough P, Soman S, Shah S, et al: Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 36:S679-S68, 2000 (suppl 1)
4. Taylor AJ, Hotchkiss D, Morse RW, McCabe J: PREPARED: Preparation for Angiography in Renal Dysfunction: A randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 114:1570-1574, 1998
5. Parfrey PS, Griffiths SM, Barrett BJ, et al: Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 320:143-149, 1989
6. Rihal C, Textor S, Grill D, et al: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105:2259-2264, 2002
7. Rich MW, Crecelius CA: Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 150:1237-1242, 1990
8. Nikolsky E, Aymong ED, Dangas G, Mehran R: Radiocontrast nephropathy: Identifying the high-risk patient and the implications of exacerbating renal function. Rev Cardiovasc Med 4:S7-S14, 2003 (suppl 1)
9. Davidson CJ, Hlatky M, Morris KG, et al: Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med 110:119-124, 1989
10. Brinker JA: The third strike. Catheter Cardiovasc Interv 57:284-285, 2002
11. Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure on mortality. A cohort analysis. JAMA 275:1489-1494, 1996
12. Abizaid AS, Clark CE, Mintz GS, et al: Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 83:260-263, 1999
13. Powe NR, Steinberg EP, Erickson JE, et al: Contrast medium-induced adverse reactions: Economic outcome. Radiology 169:163-168, 1988
14. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr: Radiocontrast medium-induced declines in renal function: A role for oxygen free radicals. Am J Physiol 258:F115-F120, 1990
15. Brezis M, Rosen S: Hypoxia of the renal medulla-Its implications for disease. N Engl J Med 332:647-655, 1995
16. Thadhani R, Pascual M, Bonventre JV: Acute renal failure. N Engl J Med 334:1448-1460, 1996
17. Andrews NP, Prasad A, Quyyumi AA: N-Acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol 37:117-123, 2001
18. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R: N-Acetyl cysteine ameliorates ischemic renal failure. Am J Physiol 272:F292-F298, 1997
19. Heyman SN, Goldfarb M, Shina A, Karmeli F, Rosen S: N-Acetylcysteine ameliorates renal microcirculation: Studies in rats. Kidney Int 63:634-641, 2003
20. Lopez Conesa E, Valero F, Nadal JC, et al: N-Acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure. Am J Physiol R730-R737, 2001
21. Salom MG, Ramirez P, Carbonell LF, et al: Protective effect of N-acetyl-L-cysteine on the renal failure induced by inferior vena cava occlusion. Transplantation 65:1315-1321, 1998
22. Safirstein R, Andrade L, Vieira JM: Acetylcysteine and nephrotoxic effects of radiographic contrast agents-A new use for an old drug. N Engl J Med 343:210-212, 2000
23. Lau J, Ioannidis JP, Schmid CH: Quantitative synthesis in systematic reviews. Ann Intern Med 127:820-826, 1997
24. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC: Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 327:248-254, 1992
25. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343:180-184, 2000
26. Baker CS, Wragg A, Kumar S, et al: A rapid protocol for the prevention of contrast-induced renal dysfunction: The RAPPID study. J Am Coll Cardiol 41:2114-2118, 2003
27. Briguori C, Manganelli F, Scarpato P, et al: Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 40:298-303, 2002
28. Laupacis A, Sackett DL, Roberts RS: An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318:1728-1733, 1988
29. Adamian MG, Moussa I, Mehran R, et al: The role of Mucomyst administration prior to percutaneous interventions on renal function in patients with chronic renal failure. J Am Coll Cardiol 39: 1A, 2002 (abstr)
30. Boccalandro F, Ahmad M, Sdringola S, Baptista E, Smalling RW: Oral acetylcysteine does not prevent contrast induced nephropathy in patients with chronic renal insufficiency undergoing cardiac catheterization. Proceedings of the American Heart Association Scientific Sessions, 2002. Available at: http://aha.agora.com/abstractviewer.search.asp. Accessed May 12, 2003
31. Tadros GM, Mouhayar EN, Akinwande AO, et al: Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. J Invasive Cardiol 15:311-314, 2003
32. Nogareda GJ, Ricci DR, Penn IM, et al: Oral N-acetylcysteine administered immediately prior to routine percutaneous coronary procedures ameliorates contrast-induced nephrotoxicity. Proceedings of the American College of Cardiology Scientific Sessions, 2003. Available at: http:// www.acc.org/2003ann_meeting/home/home.htm. Accessed June 2, 2003
33. Pai DY, Denny DF, Shanahan AJ, Ruddy MC: The effect of acetylcysteine on renal function in elderly high-risk patients exposed to arteriographic contrast dye. Am J Hypertens 16:255A, 2003 (abstr)
34. Kanderian AS, Abdelhadi RH, Bhatt DL, Schneider J, Chung MK: Hydration versus N-acetylcysteine for protection of renal function in patients with renal insufficiency undergoing percutaneous coronary intervention. Proceedings of the American College of Cardiology Scientific Sessions, 2003. Available at: http://www.acc.org/2003ann_ meeting/home/home.htm. Accessed June 2, 2003
35. Briguori C, Colombo A, Violante A, et al: High versus low dose of acetylcysteine to prevent contrast agent associated nephrotoxicity. Proceedings of the American College of Cardiology Scientific Sessions, 2003. Available at: http://www.acc.org/2003ann_meeting/home/home.htm. Accessed June 2, 2003
36. Vallero A, Cesano G, Pozzato M, et al: Contrast nephropathy in cardiac procedures: No advantages with prophylactic use of N-acetylcysteine (NAC). G Ital Nefrol 19:529-533, 2002
37. Kahlon JP, Moser L, Rosman H, et al: Effectiveness of N-acetylcysteine for the prevention of radiocontrast-induced nephropathy: Is the jury still out? Proceedings of the American Heart Association Scientific Sessions, 2002. Available at: http://aha.agora.com/abstractviewer.search.asp. Accessed May 12, 2003
38. Loutrianakis E, Stella D, Hussain A, et al: Randomized comparison of fenoldopam and N-acetylcysteine to saline in the prevention of radio-contrast induced nephropathy. Proceedings of the American College of Cardiology Scientific Sessions, 2003. Available at: http://www.acc.org/ 2003ann_meeting/home/home.htm. Accessed June 2, 2003
39. Azmus A, Manica A, Duro K, et al: The effect of N-acetylcysteine in renal function in patients undergoing coronary intervention. Am J Cardiol 90:144HA, 2002 (abstr)
40. Oldemeyer JB, Cichowski EK, Wurdeman RL, Packard KA, Biddle PW, Mooss AN: Prophylactic acetylcysteine is not effective in preventing contrast-induced nephropathy following coronary angiography. Proceedings of the American College of Cardiology Scientific Sessions, 2003. Available at: http://www.acc.org/2003ann_meeting/home/ home.htm. Accessed June 2, 2003
41. Ochoa AB, Isayenko Y, Pellizzon G, et al: Abbreviated dosing of N-acetylcysteine prevents contrast induced acute renal failure after coronary angiography and intervention. Proceedings of the American Heart Association Scientific Sessions, 2002. Available at: http://aha.agora.com/ abstractviewer.search.asp. Accessed May 12, 2003
42. Allaqaband S, Tumuluri R, Malik AM, et al: Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 57:279-583, 2002
43. Durham JD, Caputo C, Dokko J, et al: A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 62:2202-2207, 2002
44. Shyu KG, Cheng JJ, Kuan P: Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 40:1383-1388, 2002
45. Kay J, Chow WH, Chan TM, et al: Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: A randomized controlled trial. JAMA 289:553-558, 2003
46. Tepel M, Zidek W: Acetylcysteine for radiocontrast nephropathy. Curr Opin Crit Care 7:390-392, 2001
47. Holdiness MR: Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet 20:123-134, 1991
48. Chen HC, Guh JY, Lai YH: Alterations of glomerular and extracellular glutathione peroxidase levels in patients and rats with focal segmental glomerulosclerosis. J Lab Clin Med 137:279-283, 2001
49. Krzyzanowska MK, Pintilie M, Tannock IF: Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 290:495-501, 2003
50. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348:491-499, 2003
51. Barrett BJ, Carlisle EJ: Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 188:171-178, 1993
52. Rudnick MR, Goldfarb S, Wexler L, et al: Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial. The Iohexol Cooperative Study. Kidney Int 47:254-261, 1995
53. Ritchie JL, Nissen SE, Douglas JS Jr, et al: Use of nonionic or low osmolar contrast agents in cardiovascular procedures. American College of Cardiology Cardiovascular Imaging Committee. J Am Coll Cardiol 21:269-273, 1993
54. Jacobson PD, Rosenquist CJ: The introduction of low-osmolar contrast agents in radiology. Medical, economic, legal, and public policy issues. JAMA 260:1586-1592, 1988
55. Sladen RN: Will this magic bullet fly true? Crit Care Med 29:911-913, 2001
56. Serial Online. Available at: http://www.dmgstore.com/ pharmacy/prices/drugprice.asp?ndc=00087057009&trx=1z5006. Accessed: June 17, 2003